For instance, ADC Ladiratuzumab vedotin targeting ZIP6 shows clinical efficacy (231) and novel ADC BRY812 targeting ZIP6 reduces growth, migration, and stemness of colorectal cancer cells in preclinical studies (169). The gene discussed is SLC39A6; the disease is colorectal cancer.